Phase 1 and Phase 2 · Exenatide

NCT00566813 trial results

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

Number of Participants With Adverse Events Including Laboratory Abnormalities at the End of Study Participation (participants), 15 months after the last transplant. Islet Cells: 4; Islet Cells + Etanercept + Exenatide: 5.

Participants
10
Status
completed
Completed
2020-07-15
Sponsor
University of Illinois Chicago

As posted on ClinicalTrials.gov (NCT00566813), updated at source Apr 6, 2021. Read again whenever the registry updates it. Registry figures can differ from a published paper, which may use another analysis.

Primary outcome

What NCT00566813 measured first

Number of Participants With Adverse Events Including Laboratory Abnormalities at the End of Study Participationparticipants · 15 months after the last transplant · number
Islet Cellsn=4Islet Cells + Etanercept + Exenatiden=6
45
Number of Participants With Insulin Independence at End of Study Participationparticipants · End of 15 Month Study Participation/Follow-up · number
Islet Cellsn=4Islet Cells + Etanercept + Exenatiden=6
45
Number of Participants With HbA1c Less Than or Equal to 6.5 & Free of Severe Hypoglycemic Eventsparticipants · At end of 15 month study participation · number
Islet Cellsn=4Islet Cells + Etanercept + Exenatiden=6
45
Side effects by arm

Side effects in NCT00566813

Percent of participants affected, Adverse event data were collected for 1 year following the last transplant.. The most common events the registry lists.

EventIslet CellsIslet Cells + Etanercept + Exenatide
Any serious event0%33.3%
Transient anemia100%100%
Temporary nausea, vomiting, and weight loss0%100%
Increased creatinine25%33.3%
Irregular menstrual bleeding and ruptured ovarian cyst25%0%
Scalene muscle myonecrosis and vertebral osteomyelitis0%16.7%
The trial

How NCT00566813 was run

The primary purpose of this study is to demonstrate the safety of allogeneic islet transplantation in type 1 diabetic patients performed at the University of Illinois at Chicago (UIC). The purpose is to reproduce the Edmonton protocol to demonstrate that pancreatic islets isolated at UIC are safe and of sufficient quality to provide reproducible graft function.

  • Group 1 (Islet Cell Transplant): 1-3 Islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for three months post-transplant and 7-10 ng/mL therafter; tacrolimus dosed to maintain serum trough levels 3-6 ng/mL throughout the study.
  • Group 2 (Islet Cell Transplant plus): 1-3 islet transplants by the Edmonton Protocol of Steroid Free Immunosuppression using daclizumab 1 mg/kg IV immediately pre-transplant and 2, 4, 6, and 8 weeks after transplant; sirolimus dosed to maintain serum trough levels 12-15 ng/mL for 3 months post-transplant and 7-10 mg/mL thereafter; tacrolimus dosed to serum trough levels 3-6 ng/mL throughout the study; etanercept 50 mg IV pre-transplant, 25 mg subcutaneously post-transplant Days 3, 7, 10; exenatide 5-mcg subcutaneously twice daily...
Who could join the trial

Inclusion Criteria: * Type 1 diabetes \> 5 years complicated by at least one of the following situations despite intensive insulin management: * Reduced awareness of hypoglycemia at plasma glucose levels \< 54 mg/dL * Metabolic lability/instability characterized by two or more episodes of severe hypoglycemia or hospital visits for diabetic ketoacidosis over the last year * Progressive secondary complications of diabetes: * Retinopathy-three step progression using the ETDRS grading system or equivalent progression; * Nephropathy- microalbuminuria rise of 50 µg/min (72 mg/24h) over three months within the past two years despite using an ACE inhibitor; * Neuropathy-persistent gastroparesis, postural hypotension, neuropathic bowel or bladder, or severe peripheral neuropathy unresponsive to management Exclusion Criteria: * Co-existing cardiac disease: * Myocardial infarction within past six months * Angiographic evidence of non-correctable coronary artery disease * Ischemia on functional cardiac exam d. Heart failure \> NYHA II * Active alcohol or substance abuse or cigarette smoking * Psychiatric disorder: schizophrenia, bipolar disorder, or major depression that is unstable on medication * Non-adherence to prescribed regimens * Active infection including hepatitis C, hepatitis B, HIV * TB by history, current infection, or under treatment for suspected TB * History of malignancies except squamous or basal skin cancer * Stroke within the past 6 months * BMI \> 26 kg/m2 or body weight \> 70 kg at screening visit * C-peptide response to glucagon stimulation, any C-peptide ≥ 0.3 ng/mL * Inability to provide informed consent * Age less than 18 or greater than 65 years * Creatinine clearance \< 85 mL/min/1.73 m2 by 24-hour urine collection * Serum creatinine \> 1.5 mg/dL * Macroalbuminuria \> 300 mg/24h * Baseline Hb \< 12 gm/dL in women, \< 13 gm/dL in men * Baseline liver function tests outside normal range * Untreated proliferative retinopathy * Positive pregnancy test, intent for pregnancy, male's intent to procreate, unwilling to use effective contraception, breast-feeding * Previous transplant or PRA reactivity \> 20%) * Insulin requirement \> 0.7 IU/kg/day * HbA1C \> 12% * Hyperlipidemia * Chronic use of steroids * Use of coumadin or other anticoagulant (except aspirin) or PT INR \> 1.5 * Addison's disease * Allergy to radiographic contrast material

Published papers

Papers from NCT00566813

Trial averages do not predict what one person will experience. Results are shown as the registry posts them, without interpretation.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.